Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multi-Center, Double-Blind, Cross-Over Study Comparing the Efficacy and Safety of Dex-Methylphenidate Extended Release 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-Dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Next Previous
X
Search
Trial Profile

A Randomized, Multi-Center, Double-Blind, Cross-Over Study Comparing the Efficacy and Safety of Dex-Methylphenidate Extended Release 20 mg Versus Placebo at the 0.5 Hour Timepoint (Post-Dose) in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexmethylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 01 Aug 2008 Results have been published in CNS drugs. Primary and secondary endpoints met.
    • 22 Dec 2007 Status changed from recruiting to completed.
    • 19 Dec 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top